Actavia Life Sciences (Actavia Life Sciences) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Actavia Life Sciences's Free Cash Flow for the three months ended in Dec. 2023 was $-0.05 Mil. Actavia Life Sciences's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Actavia Life Sciences's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Actavia Life Sciences's current FCF Yield % is -0.41%.

The historical rank and industry rank for Actavia Life Sciences's FCF Margin % or its related term are showing as below:

RASP's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -145.04
* Ranked among companies with meaningful FCF Margin % only.

Actavia Life Sciences FCF Margin % Historical Data

The historical data trend for Actavia Life Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences FCF Margin % Chart

Actavia Life Sciences Annual Data

Trend

Jun14

Jun15

Jun16

Mar17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

FCF Margin %

Get a 7-Day Free Trial

Actavia Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Actavia Life Sciences's FCF Margin %

For the Biotechnology subindustry, Actavia Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actavia Life Sciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's FCF Margin % falls into.

Actavia Life Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Actavia Life Sciences's FCF Margin for the fiscal year that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-0.009	/	0
	=	%

Actavia Life Sciences's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.047	/	0
	=	%

Actavia Life Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Actavia Life Sciences (Actavia Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170

Website

https://www.rasna.com

Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines